TRL becomes primary distributor of Kirkstall's QuasiVivo system in the US and Canada

Triangle Research Labs, LLC (TRL) and Kirkstall, Ltd, are pleased to announce TRL as the primary distributor of Kirkstall's 3-D cell fluidic culture system, QuasiVivo®, in the US and Canada.

"We were searching for an organization to provide specialist market knowledge and help us deliver outstanding support to our US customers," said Dr. Malcolm Wilkinson, CEO of Kirkstall. "TRL has a great reputation and already supply cell culture technology that is complementary to the QuasiVivo® System."

Historically, in vitro biomedical research has relied on cell culture models developed using 6- 24- and 96- well plates, but these provide a basic model of physiological conditions in-vivo. 3-D cell culture is one of the fastest growing segments of the cell culture tools market for drug development, toxicity testing, cancer research, and stem cell regenerative medicine research.

Kirkstall's QuasiVivo® technology enables creation of cell culture models that are more predictive of what is likely to happen in the clinic, which could lead to improved patient safety and reduction of attrition in later stages of drug development.

"Researchers in cell biology are now recognizing the need for complex cell culture model systems to provide more relevant predictive value. Improvements in hepatocytes physiology and function are apparent when cells are cultured in low-shear-stress fluidics such as provided in the QuasiVivo® system," said Maureen Bunger, PhD and Technical Director at TRL. "The QuasiVivo is a highly versatile system that supports hepatocytes function for more than three weeks enabling researchers to perform longer-term experiments using primary hepatocytes than they can in a typical static culture system. It's a great complement to TRL's current product line."